MYH11 and non-small cell lung carcinoma: ,30 Our findings indicate that the presence of two distinct fibroblast populations, namely FAP+αSMA+ CAFs and MYH11+αSMA+ CAFs, is associated with adverse outcomes in patients with mTLS-positive NSCLC undergoing ICI treatment.